These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10600086)

  • 1. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.
    Polk RE; Crouch MA; Israel DS; Pastor A; Sadler BM; Chittick GE; Symonds WT; Gouldin W; Lou Y
    Pharmacotherapy; 1999 Dec; 19(12):1378-84. PubMed ID: 10600086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.
    Brophy DF; Israel DS; Pastor A; Gillotin C; Chittick GE; Symonds WT; Lou Y; Sadler BM; Polk RE
    Antimicrob Agents Chemother; 2000 Apr; 44(4):978-84. PubMed ID: 10722500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
    Polk RE; Brophy DF; Israel DS; Patron R; Sadler BM; Chittick GE; Symonds WT; Lou Y; Kristoff D; Stein DS
    Antimicrob Agents Chemother; 2001 Feb; 45(2):502-8. PubMed ID: 11158747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
    Wire MB; Ballow CH; Borland J; Shelton MJ; Lou Y; Yuen G; Lin J; Lewis EW
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2982-4. PubMed ID: 17517848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
    Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.
    Hendrix CW; Wakeford J; Wire MB; Lou Y; Bigelow GE; Martinez E; Christopher J; Fuchs EJ; Snidow JW
    Pharmacotherapy; 2004 Sep; 24(9):1110-21. PubMed ID: 15460171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
    Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
    Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.
    Veronese L; Rautaureau J; Sadler BM; Gillotin C; Petite JP; Pillegand B; Delvaux M; Masliah C; Fosse S; Lou Y; Stein DS
    Antimicrob Agents Chemother; 2000 Apr; 44(4):821-6. PubMed ID: 10722476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.
    Sadler BM; Hanson CD; Chittick GE; Symonds WT; Roskell NS
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1686-92. PubMed ID: 10390223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
    Wire MB; Shelton MJ; Studenberg S
    Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole.
    Jamis-Dow CA; Pearl ML; Watkins PB; Blake DS; Klecker RW; Collins JM
    Am J Clin Oncol; 1997 Dec; 20(6):592-9. PubMed ID: 9391548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
    Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
    J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
    Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR
    J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between ketoconazole and almotriptan in healthy volunteers.
    Fleishaker JC; Herman BD; Carel BJ; Azie NE
    J Clin Pharmacol; 2003 Apr; 43(4):423-7. PubMed ID: 12723463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M; Clay PG; Anderson PL; Glaros AG
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of didanosine formulations on the pharmacokinetics of amprenavir.
    Shelton MJ; Giovanniello AA; Cloen D; Berenson CS; Keil K; DiFrancesco R; Hewitt RG
    Pharmacotherapy; 2003 Jul; 23(7):835-42. PubMed ID: 12885096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.
    Khaliq Y; Gallicano K; Tisdale C; Carignan G; Cooper C; McCarthy A
    Br J Clin Pharmacol; 2001 Jun; 51(6):591-600. PubMed ID: 11422019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals.
    Moody DE; Walsh SL; Rollins DE; Neff JA; Huang W
    Clin Pharmacol Ther; 2004 Aug; 76(2):154-66. PubMed ID: 15289792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.